回顾现有文献，研究累及眼球和（或）眼附属器的间变性大细胞淋巴瘤（ALCL）患者，并提供一份报告，记录累及眼球和眼附属器的ALCL患者的临床过程。利用PubMed、Scopus和谷歌学术系统地检索了从开始到2023年5月为止的与眼内或附属眼结构有关的ALCL所有病例。此外，还报道了一例新的病例，添加到所有搜索发现的病例中。回顾鉴定了1680个研究，符合纳入标准的有8个。共纳入了9名患者，平均年龄为29.7岁（中位数：30.0，范围：1.3-48）。 5/9（55.6％）患者表现为原发性ALCL。最常见的眼科症状包括眼眶周围肿胀（5/8），结膜水肿（5.8）和视力减退（5/7）。最初有3名患者被误诊，由于纠正诊断的滞后时间在3周至3个月之间。所有病例的CD30表达都为阳性，而6/9患者阳性表达间变性淋巴瘤激酶，因此6/9患者被诊断为间变性淋巴瘤激酶阳性ALCL。在治疗手段方面，8/9名患者接受了化疗，4/9名患者接受了放射治疗，2名患者接受了自体干细胞移植。其中5名（55.6％）患者死于ALCL，而4名（44.4％）在最后的随访中无病存活。从ALCL初始表现到死亡、眼科表现到死亡和诊断到死亡的中位时间分别为4.12个月（范围：1.1-168.0），2.62个月（范围：1.1-144）和4.00个月（范围：0.10-168）。中位随访时间为21.0个月（范围：1.1-168.0）。累及眼球和眼附属器的ALCL是一种罕见且高度恶性的肿瘤，可能模拟良性临床病情。早期活检和采用CHOP等化疗方案及放射治疗的积极治疗可能有助于疾病处理。Copyright © 2023 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc.

To review the existing literature on patients with anaplastic large cell lymphoma (ALCL) affecting the globe and/or ocular adnexa, and to present a report documenting the clinical course of a patient with ALCL that involved their globe and ocular adnexa.PubMed, Scopus, and Google scholar were systematically searched for all cases of ALCL involving intraocular or adnexal ocular structures from inception to May 2023. Moreover, a new reported case added to the cases found in searches.The review identified 1680 studies, with 8 meeting inclusion criteria. A total of 9 patients were included with a mean age of 29.7 years (median: 30.0, range: 1.3-48). Primary ALCL was present in 5/9 (55.6%) patients. The most common ophthalmic manifestations included periorbital swelling (5/8), chemosis (5.8), and decreased vision (5/7). Misdiagnoses were initially made in 3 patients, and the lag time to correct diagnosis from 3 weeks to 3 months. CD30 expression was positive in all cases, and 6/9 patients were positive for anaplastic lymphoma kinase, resulting in 6/9 patients being diagnosed with anaplastic lymphoma kinase-positive ALCL. In terms of management modalities, chemotherapy was administered in 8/9 patients, while radiation therapy was utilized in 4/9 patients, and 2 underwent autologous stem cell transplantation. Five (55.6%) patients succumbed to ALCL while 4 (44.4%) were alive and disease-free at the last follow-up. The median times from the initial presentation of ALCL to death, ophthalmic presentation to death, and diagnosis to death were 4.12 months (range: 1.1-168.0), 2.62 months (range: 1.1-144), and 4.00 months (range: 0.10-168), respectively. The median follow-up duration was 21.0 months (range: 1.1-168.0).ALCL involving the globe and ocular adnexa is a rare and highly malignant tumor that can mimic benign clinical conditions. Early biopsy and aggressive treatment with chemotherapy regimens such as CHOP and radiation therapy may be useful.Copyright © 2023 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc.